Observational study finds higher ATF4 levels linked to aggressive lung cancer in older adults — Evidence Review
Published in Nature, by researchers from University of Gothenburg
Researched by
— the AI search engine for science
Table of Contents
A new study links aging to changes in lung cancer biology, identifying the stress-response protein ATF4 as a driver of metastasis in older patients. Related research broadly supports these findings, indicating that ATF4 is associated with more aggressive tumor behavior and poorer outcomes across several cancer types, and that age-related differences in tumor biology are often overlooked in research and treatment approaches, as discussed in the original source.
- Numerous studies have shown that ATF4 upregulation contributes to cancer cell survival, increased metastasis, and worse prognosis in lung, breast, gastric, and esophageal cancers, aligning with the new study's findings that high ATF4 is linked to more aggressive lung cancer in older adults 1 5 11 12 13.
- Existing research emphasizes the importance of considering biological aging in cancer treatment, highlighting that older patients often have different tumor characteristics and vulnerabilities that may affect therapy response and outcomes, supporting the new study’s call for age-adapted treatment approaches 6 7 8 9.
- Previous attempts to target ATF4-related pathways in cancer have yielded mixed results, but the new study suggests that age and tumor-specific ATF4 activity may help identify patient groups most likely to benefit from such therapies 2 3 5 13.
Study Overview and Key Findings
While lung cancer is most prevalent in older adults, much of the basic research relies on young animal models, potentially missing important age-related differences. This study addresses that gap by directly comparing lung tumors in young and older mice and analyzing data from about 1,000 older lung cancer patients. The work is timely, as the population ages and the need for age-adapted cancer therapies grows. The study’s central finding is that aging changes the biological behavior of lung tumors, making them more likely to metastasize via an age-dependent hijacking of the ATF4-regulated stress response.
| Property | Value |
|---|---|
| Study Year | 2026 |
| Organization | University of Gothenburg |
| Journal Name | Nature |
| Authors | Angana A. H. Patel, Jozefina J. Dzanan, Kevin X. Ali, Ella A. Eklund, Samantha W. Alvarez, Dorota Raj, Martin Dankis, Ilayda Altinönder, Maria Schwarz, Kristell Le Gal, Emre Bedel, Ahmed Ezat El Zowalaty, Emma Jonasson, Heba Albatrok, Nadia Gul, Jozef P. Bossowski, Ray Pillai, Patrick Micke, Johan Botling, Levent M. Akyürek, Davide Angeletti, Sama I. Sayin, Anetta Härtlova, Thales Papagiannakopoulos, Roger Olofsson Bagge, Anders Ståhlberg, Andreas Hallqvist, Clotilde Wiel, Volkan I. Sayin |
| Population | Older adults with lung cancer |
| Sample Size | about 1,000 lung cancer patients |
| Methods | Observational Study |
| Outcome | Tumor behavior, spread, and survival rates |
| Results | Higher ATF4 levels linked to more aggressive lung cancer |
Literature Review: Related Studies
To contextualize these findings, we searched the Consensus paper database, which includes over 200 million research papers. Three specific search queries were used to identify related studies:
Below, we organize key insights from the literature into major thematic questions:
| Topic | Key Findings |
|---|---|
| How does ATF4 influence cancer metastasis and prognosis? | - ATF4 upregulation drives metastasis and poor prognosis in multiple cancers, including lung, breast, gastric, and esophageal cancers 1 5 11 12 13. - ATF4 activity supports survival mechanisms in stressed tumor cells, facilitating tumor spread 1 2 3 11 12. |
| What is the relationship between aging and cancer treatment outcomes? | - Aging alters tumor biology and increases vulnerability to treatment toxicity, necessitating comprehensive geriatric assessment for older cancer patients 6 7 8 9. - Biological age and aging biomarkers may guide personalized treatment strategies 8 9. |
| Can targeting ATF4 or stress-response pathways improve cancer therapy? | - Inhibiting ATF4 or its downstream pathways reduces metastasis in preclinical models, but clinical success may depend on patient selection and tumor context 1 2 5 13. - Previous clinical trials struggled due to lack of stratification by age or ATF4 status 2 5 13. |
| How do current research models and clinical practices address aging in cancer? | - Most cancer research is conducted in young animal models, potentially overlooking age-related tumor features 6 8 9. - Guidelines recommend integrating geriatric assessment into treatment planning for older adults 6 7 9. |
How does ATF4 influence cancer metastasis and prognosis?
Research consistently finds that ATF4 is a central regulator of cancer cell adaptation to stress, promoting survival, metastasis, and poor clinical outcomes in several cancer types. The new study’s identification of ATF4 as a driver of lung cancer metastasis in older adults is strongly supported by previous findings across tumor types.
- ATF4 induces protective mechanisms in tumor cells, enabling resistance to cell death and supporting metastasis in lung, breast, gastric, and esophageal cancers 1 5 11 12 13.
- High ATF4 expression is repeatedly associated with worse patient survival and increased risk of relapse or metastasis 1 5 11 12 13.
- In lung cancer specifically, ATF4-dependent pathways prevent anoikis and support tumor colonization of distant organs 1.
- In breast cancer, both overexpression and functional activity of ATF4 correlate with decreased survival and more aggressive tumor behavior 11 13.
- Targeting ATF4 or its downstream effectors can inhibit proliferation, migration, and invasion in preclinical cancer models 5 11 12.
What is the relationship between aging and cancer treatment outcomes?
The literature highlights that older adults with cancer face unique challenges due to age-related physiological changes, comorbidities, and altered tumor biology. These factors affect both disease progression and the risks and benefits of cancer therapy.
- Geriatric assessment is recommended for all patients aged 65 and older to identify vulnerabilities that standard oncology assessments may miss 6 7 9.
- Biological aging can profoundly influence tumor behavior, treatment tolerance, and ultimately survival outcomes 8 9.
- Older patients are at higher risk of both overtreatment (with excess toxicity) and undertreatment (with inadequate disease control) 8.
- Biomarkers reflecting biological age may help to optimize individual treatment regimens 8 9.
- Comprehensive geriatric assessments have been shown to improve clinical outcomes and communication among clinicians, patients, and caregivers 6 9.
Can targeting ATF4 or stress-response pathways improve cancer therapy?
Evidence suggests that ATF4 is a promising therapeutic target, but clinical translation has been limited by insufficient patient stratification and uncertainty about which patients will benefit most.
- Inhibition of ATF4 or related metabolic pathways reduces metastasis in preclinical models, including lung and breast cancer 1 5 11 13.
- Previous clinical trials of drugs targeting stress-response pathways have often failed, possibly because they did not identify or select patients with high ATF4 activity or relevant tumor characteristics 2 5 13.
- There is growing recognition that patient age, tumor biology, and stress-response status must be considered together to optimize targeted therapy 2 5 13.
- The new study’s suggestion that older patients with elevated tumor ATF4 levels may benefit most from ATF4-targeted therapy is supported by these findings 5 13.
How do current research models and clinical practices address aging in cancer?
The gap between preclinical research (often using young animals) and the real-world population (predominantly older adults) has been a persistent barrier in oncology research and drug development.
- Most laboratory cancer models use young animals, failing to capture the impact of aging on tumor biology and therapy response 6 8 9.
- Clinical guidelines increasingly call for the integration of geriatric assessment into care planning for older adults with cancer 6 7 9.
- There is a recognized need for age-appropriate preclinical models and for routine use of aging biomarkers in both research and clinical practice 6 8 9.
- The new study’s approach—using older animal models and patient data—addresses these gaps and is in line with emerging best practices 6 8 9.
Future Research Questions
Further research is needed to understand the interplay between aging, stress-response pathways like ATF4, and cancer progression and treatment. The following questions highlight key areas where more investigation could inform both basic science and clinical care.
| Research Question | Relevance |
|---|---|
| Does inhibiting ATF4 improve outcomes in older lung cancer patients with high ATF4 activity? | Determining whether targeting ATF4 specifically benefits older patients with high ATF4 expression could enable more personalized and effective therapies, addressing previous failures in clinical translation 2 5 13. |
| How does biological aging alter the tumor microenvironment and metastatic potential? | Understanding how aging changes interactions between tumor cells and their microenvironment could identify new therapeutic targets and explain age-related differences in cancer progression 8 9. |
| Which biomarkers can best stratify older cancer patients for targeted therapies? | Identifying reliable biomarkers, including ATF4 and aging markers, may guide treatment selection and improve outcomes by matching patients to the most appropriate therapies 8 9 13. |
| What are the mechanisms by which ATF4 promotes metastasis in different cancer types? | Mechanistic studies could reveal whether ATF4 drives metastasis through common or distinct pathways across tumor types, informing the development of broad or tumor-specific therapies 1 3 5 11 12 13. |
| How can preclinical models be improved to better reflect aging-related changes in cancer? | Developing age-appropriate animal and cell models will help bridge the gap between laboratory research and clinical reality, leading to more relevant findings for older cancer patients 6 8 9. |